- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/56 - Amides
Patent holdings for IPC class C07D 213/56
Total number of patents in this class: 762
10-year publication summary
|
69
|
35
|
60
|
55
|
47
|
36
|
37
|
48
|
34
|
27
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4850 |
20 |
| Atnx Spv, LLC | 39 |
18 |
| Corteva Agriscience LLC | 2692 |
16 |
| Gilead Sciences, Inc. | 2060 |
14 |
| Takeda Pharmaceutical Company Limited | 2706 |
11 |
| Neurocrine Biosciences, Inc. | 433 |
11 |
| Purdue Pharma L.P. | 502 |
9 |
| The Salk Institute for Biological Studies | 446 |
8 |
| Theravance Biopharma R&D IP, LLC | 456 |
8 |
| F. Hoffmann-La Roche AG | 7947 |
7 |
| Bayer Pharma AG | 1054 |
7 |
| CHDI Foundation, Inc. | 106 |
7 |
| Ono Pharmaceutical Co., Ltd. | 430 |
7 |
| Tetra Discovery Partners, LLC | 11 |
7 |
| Vectus Biosystems Limited | 35 |
7 |
| Merck Sharp & Dohme LLC | 3756 |
7 |
| Hoffmann-La Roche Inc. | 3484 |
6 |
| Genentech, Inc. | 4012 |
6 |
| Janssen Pharmaceutica N.V. | 3370 |
6 |
| Merck Patent GmbH | 5773 |
6 |
| Other owners | 574 |